4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

April 13, 2023

https://www.globenewswire.com/news-release/2023/04/13/2646130/0/en/4DMT-to-Present-Interim-Data-from-4D-150-Phase-1-2-PRISM-Clinical-Trial-for-Wet-AMD-at-ARVO-2023-and-Promotes-Robert-Kim-M-D-to-Chief-Medical-Officer.html

EMERYVILLE, Calif., April 13, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq:FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced an oral presentation of interim data from the 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23-27, 2023 in New Orleans, Louisiana. 4D-150 is designed for single, low-dose intravitreal delivery of a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi and is currently in clinical development for wet AMD and diabetic macular edema (DME).

Read more at globenewswire.com

Related news for (FDMT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.